Targeting cyclooxygenase-2 in recurrent non–small cell lung cancer: a phase II trial of celecoxib and docetaxel
I Csiki, JD Morrow, A Sandler, Y Shyr, J Oates… - Clinical cancer …, 2005 - AACR
Abstract Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG)
synthesis and is overexpressed in 70% to 90% of non–small cell lung cancers (NSCLC) …
synthesis and is overexpressed in 70% to 90% of non–small cell lung cancers (NSCLC) …
COX-2 inhibition and lung cancer
AB Sandler, SM Dubinett - Seminars in oncology, 2004 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …
cancer. In non-small cell lung cancer (NSCLC), COX-2 is overexpressed in most …
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non–small cell lung cancer
Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer
NK Altorki, RS Keresztes, JL Port, DM Libby… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Preclinical studies suggest that treatment with a selective cyclo-oxygenase-2 (COX-
2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with …
2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with …
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
HJM Groen, H Sietsma, A Vincent… - Journal of clinical …, 2011 - ascopubs.org
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
[HTML][HTML] Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or …
Purpose Overexpression of COX-2 correlates with advanced stage and worse outcomes in
non–small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2 …
non–small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2 …
[HTML][HTML] Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non–small-cell lung cancer with …
MJ Edelman, X Wang, L Hodgson… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - Taylor & Francis
Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
Chemotherapy Induces the Expression of Cyclooxygenase-2 in Non–Small Cell Lung Cancer
NK Altorki, JL Port, F Zhang, D Golijanin, HT Thaler… - Clinical cancer …, 2005 - AACR
Purpose: To determine the effect of taxane-based chemotherapy on intratumoral levels of
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) in patients with non–small cell …
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) in patients with non–small cell …
[HTML][HTML] Dimethyl celecoxib as a novel non–cyclooxygenase 2 therapy in the treatment of non–small cell lung cancer
OBJECTIVES: The cyclooxygenase 2 enzyme has become a therapeutic target in cancer
treatment. Cyclooxygenase 2 blockade with selective inhibitors increases apoptosis and …
treatment. Cyclooxygenase 2 blockade with selective inhibitors increases apoptosis and …